3597-42-0

Upstream product

• 77029-01-7 6-methoxy-[1]naphthonitrile 
• 36112-55-7 2-methoxy-8,9-dihydro-7H-benzocycloheptene 
• 2437-17-4 6-hydroxy-1-naphthoic acid 
• 61109-48-6 6-methoxy-1-naphthalenecarboxylic acid methyl ester 
• 6500-64-7 5-(3'-methoxyphenyl)pentanoic acid 
• 36112-54-6 2-methoxy-6,7,8,9-tetrahydro-5H-benzocycloheptan-5-ol 
• 6500-65-8 2-methoxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one 
• 83379-67-3 2-(2,4-dinitrophenyl)-7-methoxyisoquinolinium bromide 
• 82589-61-5 Ethyl 6-methoxy-1-naphthoate 
• 63469-49-8 1-iodo-6-methoxynaphthalene 
• 68-12-2 N,N-dimethyl-formamide 
• 61109-49-7 1-Hydroxymethyl-6-methoxynaphthalene 
• 36112-56-8 3-methoxy-5H-benzo[7]annulene 

Downstream Products

• 82590-38-3 (Z)-5-(6-Methoxy-naphthalen-1-yl)-4-nitro-pent-4-enoic acid ethyl ester 
• 571206-45-6 6-hydroxy-1-naphthaldehyde 
• 83379-75-3 benzyl (6-methoxynaphthyl)carbamate 
• 82589-57-9 3-Methoxy-7,9,10,11,11a,12-hexahydrobenzopyrrolo<1,2-b>isoquinoline 
• 192384-22-8 4-Fluoro-2-[1-(6-methoxy-naphthalen-1-yl)-ethyl]-benzoic acid 
• 192384-04-6 4-fluoro-2-[1-(3-methoxynaphthoyl)]benzoic acid 
• 192384-21-7 1-[4-Fluoro-2-(6-methoxy-naphthalen-1-ylmethyl)-phenyl]-ethanone 

Relevant academic research and scientific papers

Organocatalytic Atroposelective Arylation of 2-Naphthylamines as a Practical Approach to Axially Chiral Biaryl Amino Alcohols

The first phosphoric acid catalyzed direct arylation of 2-naphthylamines with iminoquinones for the atroposelective synthesis of axially chiral biaryl amino alcohols has been developed. This reaction constitutes a highly functional-group-tolerant route for the rapid construction of enantioenriched axially chiral biaryl amino alcohols, and is a rare example of 2-naphthylamines acting as nucleophiles in an organocatalytic enantioselective transformation. Furthermore, the products, which feature various halogen atoms, provide access to structurally diverse axially chiral amino alcohols through further transformations.

In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor

There is still a need for additional scaffolds to further explore tissue selectivity and improving efficacy of selective estrogen receptor modulators (SERMs). A series of hydroxyl substituted diphenylnaphthyl alkene ligands for the two estrogen receptors are described that arose from an initial de novo designed diphenylnaphthyl propylene ligand 1. All compounds gave Kis under 10 nM when assayed in the presence of ERα. Generally these compounds had very high affinity for both ER isotypes. Moving the hydroxyl group on naphthalene from the 6- to the 5-position of the α-naphthalene attached compounds (6b and 6e vs 6c and 6f) had little affect on ER binding nor did altering the position of the naphthalene attachment (α or β) to the alkene moiety. In transfection assays none of the compounds displayed agonistic activity in the absence of E2. In MCF-7 proliferation assays 6a-d, 6f and 12a-c successfully abrogated E2 stimulation and resulted in greater than 50% inhibition at 1 μM, a level of efficacy similar to that obtained when the cells were treated with raloxifene. Our results show that this new class of SERMs are good candidates for further study as therapeutic agents for the treatment of breast cancer and osteoporosis.

Fluorine-substituted derivatives of the carcinogenic dihydrodiol and diol epoxide metabolites of 7-methyl-, 12-methyl- and 7,12-dimethylbenz[a]anthracene

Stereospecific syntheses of the trans-3,4-dihydrodiol metabolites of 9- and 10-fluoro-7, 12-dimethylbenz[alanthracene, -7-methylbenz[a]anthracene, and -12-methylbenz[a]anthracene are described. These dihydrodiols are putative proximate carcinogenic metabolites that undergo activation by the P-450 microsomal enzymes to ultimate carcinogenic anti- and syn-diol epoxide metabolites that bind to nucleic acids in vivo. Syntheses of several of the anti- diol epoxide metabolites are also described.

Chemical process for halogenating 2-methyl-6-methoxynaphthalene

A process for the preparation of a compound of formula (I): STR1 in which X and Y are identical and represent halogen, or X is halogen and Y is hydrogen, which comprises halogenating 2-methyl-6-methoxynaphthalene, of formula (II): STR2 in the presence of a free radical initiator.

Synthesis of Hexahydropyrroloisoquinolines - Analogs of Phenanthroindolizidine Anticancer Alkaloids

A convenient preparative route has been developed for the synthesis of hexahydropyrroloisoquinolines involving condensation of an araldehyde with ethyl 4-nitrobutanoate followed by LAH reduction and subsequent cyclization with H2SO4 to 2-arylmethylpyrrolidines.The latter on formylation and Bischler-Napieralsky cyclization followed by NaBH4 reduction give the required pyrroloisoquinolines.Using this method, 8-methoxy-1,2,3,5,10,10a-hexahydropyrroloisoquinoline (IXa); 7,8-dimethoxy-1,2,3,5,10,10a-hexahydropyrroloisoquinoline (IXb); 7,9,10,11,11a,12-hexahydrobenzopyrroloisoquinoline (Xa); 3-methoxy-7,9,10,11,11a,12-hexahydrobenzopyrroloisoquinoline (Xb); 7,7a,8,9,10,12-hexahydrobenzopyrroloisoquinoline (XIa); 3-methoxy-7,7a,8,9,10,12-hexahydrobenzopyrroloisoquinoline (XIb) and 2,3-dimethoxy-7,7a,8,9,10,12-hexahydrobenzopyrroloisoquinoline (XIc) have been synthesized.None of these compounds has shown any noteworthy anticancer activity while few have exhibited interesting antihistaminic, β-blocking, hypertensive, antiinflammatory and antireserpine activities.